X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (84777) 84777
Newsletter (19297) 19297
Newspaper Article (3553) 3553
Book Chapter (203) 203
Transcript (195) 195
Magazine Article (179) 179
Dissertation (108) 108
Conference Proceeding (71) 71
Publication (67) 67
Trade Publication Article (25) 25
Book / eBook (23) 23
Book Review (17) 17
Streaming Video (12) 12
Web Resource (11) 11
Reference (10) 10
Government Document (2) 2
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
lung cancer, non-small cell (57054) 57054
humans (51547) 51547
science & technology (47611) 47611
life sciences & biomedicine (45592) 45592
cancer (33693) 33693
oncology (31782) 31782
research (29190) 29190
female (28485) 28485
male (28404) 28404
lung neoplasms - pathology (24391) 24391
middle aged (24276) 24276
aged (23384) 23384
lung cancer (23125) 23125
carcinoma, non-small-cell lung - pathology (22261) 22261
care and treatment (21372) 21372
carcinoma, non-small-cell lung - drug therapy (18703) 18703
lung neoplasms - drug therapy (18324) 18324
oncology, experimental (17372) 17372
non-small cell lung cancer (16024) 16024
lung cancer, small cell (15651) 15651
adult (14697) 14697
prognosis (14282) 14282
chemotherapy (12876) 12876
carcinoma, non-small-cell lung - genetics (12062) 12062
lung neoplasms - genetics (11964) 11964
neoplasm staging (11232) 11232
aged, 80 and over (9768) 9768
analysis (9757) 9757
respiratory system (9729) 9729
metastasis (9612) 9612
lung neoplasms - mortality (9559) 9559
carcinoma, non-small-cell lung - mortality (9401) 9401
genetic aspects (9060) 9060
physical fitness (8609) 8609
treatment outcome (8271) 8271
tumors (8172) 8172
lung neoplasms - metabolism (8149) 8149
carcinoma, non-small-cell lung - metabolism (7987) 7987
non-small cell lung carcinoma (7919) 7919
lung neoplasms - surgery (7082) 7082
carcinoma, non-small-cell lung - surgery (7014) 7014
mutation (6862) 6862
antineoplastic combined chemotherapy protocols - therapeutic use (6780) 6780
cell line, tumor (6682) 6682
health aspects (6659) 6659
surgery (6373) 6373
retrospective studies (6370) 6370
radiotherapy (5874) 5874
apoptosis (5857) 5857
survival rate (5592) 5592
animals (5478) 5478
antineoplastic agents - therapeutic use (5306) 5306
drug therapy (5302) 5302
cancer therapies (5283) 5283
survival analysis (5250) 5250
development and progression (5219) 5219
hematology, oncology and palliative medicine (5192) 5192
epidermal growth factor (5072) 5072
clinical trials (5033) 5033
patients (4966) 4966
carcinoma, non-small-cell lung - radiotherapy (4908) 4908
lung neoplasms - therapy (4895) 4895
carcinoma, non-small-cell lung - therapy (4870) 4870
medical research (4859) 4859
lung neoplasms - radiotherapy (4752) 4752
respiratory tract diseases (4453) 4453
non-small-cell lung cancer (4452) 4452
nsclc (4447) 4447
antineoplastic agents (4423) 4423
abridged index medicus (4413) 4413
antimitotic agents (4231) 4231
gene expression (4222) 4222
immunohistochemistry (4196) 4196
lung neoplasms - diagnosis (4047) 4047
immunotherapy (4008) 4008
carcinoma, non-small-cell lung - diagnosis (3968) 3968
patient outcomes (3859) 3859
biochemistry (3850) 3850
medicine, experimental (3735) 3735
mice (3615) 3615
universities and colleges (3591) 3591
pharmaceutical industry (3558) 3558
disease-free survival (3532) 3532
medical prognosis (3498) 3498
proteins (3496) 3496
follow-up studies (3493) 3493
risk factors (3428) 3428
pharmacology & pharmacy (3292) 3292
diagnosis (3290) 3290
cell biology (3243) 3243
kinases (3181) 3181
carcinoma, non-small-cell lung - secondary (3170) 3170
gene expression regulation, neoplastic (3161) 3161
combined modality therapy (3156) 3156
medicine & public health (3085) 3085
lung neoplasms - diagnostic imaging (3077) 3077
carcinoma, non-small-cell lung - diagnostic imaging (3048) 3048
radiology, nuclear medicine & medical imaging (3030) 3030
adenocarcinoma - pathology (2974) 2974
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (104527) 104527
Chinese (1810) 1810
French (1186) 1186
Japanese (1173) 1173
German (553) 553
Spanish (254) 254
Polish (219) 219
Korean (209) 209
Russian (203) 203
Portuguese (133) 133
Italian (101) 101
Turkish (84) 84
Czech (57) 57
Hungarian (45) 45
Dutch (21) 21
Norwegian (17) 17
Bulgarian (16) 16
Serbian (15) 15
Danish (14) 14
Romanian (13) 13
Croatian (9) 9
Slovak (9) 9
Finnish (8) 8
Icelandic (8) 8
Lithuanian (7) 7
Hebrew (5) 5
Swedish (5) 5
Persian (2) 2
Belarusian (1) 1
Bosnian (1) 1
Slovenian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 11/2014, Volume 371, Issue 21, pp. 1963 - 1971
Journal Article
The New England journal of medicine, ISSN 1533-4406, 08/2017, Volume 377, Issue 9, pp. 829 - 838
...–small-cell lung cancer. Importantly, it reduced the risk of CNS relapse. 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2019, Volume 381, Issue 21, pp. 2020 - 2031
Patients with advanced non–small-cell lung cancer with a PD-L1 expression level of 1... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antineoplastic Agents, Immunological - administration & dosage | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Lung Neoplasms - metabolism | Middle Aged | Carcinoma, Non-Small-Cell Lung - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Ipilimumab - adverse effects | Nivolumab - adverse effects | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Agents, Immunological - adverse effects | B7-H1 Antigen - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Ipilimumab - administration & dosage | Nivolumab - administration & dosage | Lung cancer, Non-small cell | Drug therapy | Patient outcomes | Ipilimumab | Testing | Small cell lung carcinoma | Lung cancer | Non-small cell lung carcinoma | Oncology | Cancer therapies | Chemotherapy | Immunotherapy | PD-L1 protein | Biomarkers | Clinical medicine | Mutation | Drug dosages | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus | B7-H1 Antigen | Carcinoma, Non-Small-Cell Lung | Antineoplastic Combined Chemotherapy Protocols | Cellular Biology | Lung Neoplasms | Life Sciences | Antineoplastic Agents, Immunological | Nivolumab
Journal Article
The New England journal of medicine, ISSN 1533-4406, 05/2018, Volume 378, Issue 22, pp. 2078 - 2092
The addition of pembrolizumab to chemotherapy for metastatic lung cancer without EGFR or ALK mutations resulted in better progression-free and overall survival than chemotherapy alone... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Carcinoma, Non-Small-Cell Lung - secondary | Aged, 80 and over | Adult | Female | Lung Neoplasms - genetics | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Agents, Immunological - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Treatment outcome | Care and treatment | Chemotherapy | Usage | Analysis | Lung cancer, Non-small cell | Drug therapy | Cancer | Epidermal growth factor receptors | Laboratories | Lung cancer | Non-small cell lung carcinoma | Cytotoxicity | Metastasis | Patients | Cancer therapies | Metastases | Pembrolizumab | Hospitals | Platinum | PD-L1 protein | Response rates | Death | Mutation | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 03/2014, Volume 370, Issue 13, pp. 1189 - 1197
...–small-cell lung cancer (NSCLC), ALK rearrangement occurs in approximately 5% of cases. 2 – 8 ALK -rearranged tumors depend on ALK for growth and survival and show marked sensitivity to ALK inhibitors such as crizotinib... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Sulfones - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Recombination, Genetic | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Treatment Outcome | Sulfones - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Maximum Tolerated Dose | Receptor Protein-Tyrosine Kinases - genetics | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Sulfones - administration & dosage | Antimitotic agents | Care and treatment | Dosage and administration | Research | Lung cancer, Non-small cell | Antineoplastic agents | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Insulin-like growth factors | Dehydration | Kinases | Patients | Lymphoma | Gene amplification | Vomiting | Gene rearrangement | Hypophosphatemia | Antitumor activity | Mutation | Pharmaceutical industry | Protein-tyrosine kinase | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had similar response rates, but osimertinib... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages